Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Protalix BioTherapeuticsPLX +2.18%54 3-Year EBITDA Growth Rate is 44.50% as of Jun. 2026, which is 253% above its 10-year median of 12.60. GuruFocus rates PLX with a GF Scoreâ„¢ of 54/100 and a GF Valueâ„¢ of $2.20 (Fairly Valued). The stock has 4 warning signs investors should review. Among 1,130 Biotechnology companies, Protalix BioTherapeutics ranks better than 81.15% on this metric.
During the past 12 months, Protalix BioTherapeutics's average EBITDA Per Share Growth Rate was 199.10% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 44.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Protalix BioTherapeutics was 53.40% per year. The lowest was -84.50% per year. And the median was 12.60% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Protalix BioTherapeutics 3-Year EBITDA Growth Rate Related Terms
PLX vs GLSI, DTIL, NERV: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, Protalix BioTherapeutics's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Protalix BioTherapeutics 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Protalix BioTherapeutics's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Protalix BioTherapeutics's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 44.50% mean?
Protalix BioTherapeutics (PLX) has a 3-Year EBITDA Growth Rate of 44.50% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Protalix BioTherapeutics and its competitors. This is 253% above median its historical median of 12.60. According to the industry distribution chart, Protalix BioTherapeutics ranks #213 out of 1130 companies in the Biotechnology industry, placing it in the top 18.8%.
Is Protalix BioTherapeutics' 3-Year EBITDA Growth Rate too high?
Protalix BioTherapeutics' current 3-Year EBITDA Growth Rate of 44.50% is 253% above median its 10-year median of 12.60. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.85. Protalix BioTherapeutics' value of 44.50% is 199.7% above this industry median. Based on the distribution chart, Protalix BioTherapeutics ranks #213 out of 1130 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Protalix BioTherapeutics has a GF Score™ of 54/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Protalix BioTherapeutics' 3-Year EBITDA Growth Rate compare to GLSI and DTIL?
According to the Biotechnology industry distribution chart, Protalix BioTherapeutics ranks #213 out of 1130 companies for 3-Year EBITDA Growth Rate. This places Protalix BioTherapeutics in the top 19% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 14.85. Protalix BioTherapeutics' value of 44.50% is 199.7% above this benchmark. While the company's 10-year median is 12.60 vs. the industry median of 14.85, Protalix BioTherapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.85, based on 1,130 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Protalix BioTherapeutics's current 3-Year EBITDA Growth Rate of 44.50% is 199.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Protalix BioTherapeutics and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Protalix BioTherapeutics's current 3-Year EBITDA Growth Rate is 44.50%, which is 253% above median its own 10-year median of 12.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Protalix BioTherapeutics stock overvalued right now?
Based on GuruFocus' analysis, Protalix BioTherapeutics (PLX) is currently considered Fairly Valued. The stock's GF Value™ is $2.20, compared to a current price of $2.34 — trading 6.4% above its estimated fair value. The current 3-Year EBITDA Growth Rate is 44.50%, which is 253% above median its 10-year median of 12.60 and 199.7% above the Biotechnology industry median of 14.85. Protalix BioTherapeutics' overall GF Score™ is 54/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Protalix BioTherapeutics (PLX), the current 3-Year EBITDA Growth Rate is 44.50% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Protalix BioTherapeutics (PLX) Overvalued in 2026?
Based on GuruFocus' analysis, Protalix BioTherapeutics stock appears to be overvalued.
The current stock price of $2.34 is trading 6.4% above its estimated GF Value™ of $2.20.
GuruFocus considers Protalix BioTherapeutics to be Fairly Valued.
Key valuation signals for PLX:
3-Year EBITDA Growth Rate: 44.50% (253% above median its 10-year median of 12.60)
GF Value™: $2.20 vs. price of $2.34 (6.4% above fair value)
Industry Position: 199.7% above the Biotechnology median (#213 of 1130)
No single metric tells the full story. See the PLX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Protalix BioTherapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, production, and commercialization of therapeutics for rare diseases with important unmet needs. ProCellEx, a proprietary plant cell-based protein expression system, represents a new method for developing recombinant proteins in an industrial-scale manner. corporate includes the development of treatments for rare and orphan diseases. The Company operates as a single operating segment in Israel.
54GF Score
Get the complete analysis for PLX
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PLX has been successfully added to your 
